NCT04806256

Brief Summary

This project is based on artificial intelligence (AI) algorithms to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the Clinical Decision support system of traditional Chinese medicine intervention for dry eye, secondly, a real-world prospective cohort study design is adopted, the CDSS system is used in the ophthalmology clinic, and its practical application effect on patients with dry eye is evaluated.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 11, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 6, 2020

Completed
6 months until next milestone

First Posted

Study publicly available on registry

March 19, 2021

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

March 19, 2021

Status Verified

March 1, 2021

Enrollment Period

1.6 years

First QC Date

September 6, 2020

Last Update Submit

March 17, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Ocular Surface Disease Index

    Ocular Surface Disease Index (OSDI) is a potential useful instrument for the assessment of vision.

    Change from Before OSDI at 12 months after treatment

  • Meibomain Gland Scale

    Meibomian gland function score (MGFS) is used to evaluate the function of the meibomian glands and whether there is meibomian gland dysfunction.

    Change from Before MGFS at 12 months after treatment

Secondary Outcomes (2)

  • Tear Meniscus Height

    Change from Before TMH at 12 months after treatment

  • Tear Break up time

    Change from Before TBUT at 12 months after treatment

Study Arms (2)

CDSS group

EXPERIMENTAL

Subjects' treatment regimens were influenced by the CDSS, which was the recommended system for Tradictional Chinese Medicine treatment of dry eye.

Behavioral: Clinical Decision Support System

non-CDSS group

ACTIVE COMPARATOR

The treatment of the subjects was routine and not affected by the CDSS for Tradictional Chinese Medicine.

Other: Routine intervention

Interventions

This project is based on the artificial intelligence (AI) algorithm to screen the effective methods of traditional Chinese medicine intervention for dry eye and its applicable conditions, and optimize the traditional Chinese medicine intervention plan for dry eye through the evaluation of evidence-based medicine and expert consensus, and construct the traditional Chinese medicine intervention Clinical Decision Support Systems (CDSS) for dry eye. At the same time, the CDSS is provided to clinicians for their selection.

CDSS group

The routine intervention without CDSS is also the clinically common intervention at present.

non-CDSS group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ages 18 to 80 year-old.
  • Meet the diagnostic criteria for dry eye, including ocular surface symptoms and signs.

You may not qualify if:

  • There are contradictions in diagnostic information, and the real condition of the disease is doubtful;
  • The absence of necessary observation indicators;
  • Lack of necessary prognostic information;
  • The informed consent is not approved.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Third Hospital

Beijing, China

RECRUITING

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Study Officials

  • Liyuan Tao, PhD

    Peking University Third Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 6, 2020

First Posted

March 19, 2021

Study Start

July 11, 2020

Primary Completion

March 1, 2022

Study Completion

December 1, 2022

Last Updated

March 19, 2021

Record last verified: 2021-03

Locations